Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared HolzПодробнее

The direction of M&A in biotech is very, very vast, says Oppenheimer's HolzПодробнее

Medical device companies 'clear beneficiary' following Humana's warning, says Mizuho's Jared HolzПодробнее

Trader says weakness in tech stocks not a correction, there's just more dispersionПодробнее

Blocking the Horizon-Amgen deal will be worse for pharma than for biotech, says Mizuho's Jared HolzПодробнее

Top UK Scientist & Dr Gives Warning About Oats! (Why It's Changed My Mind About Oats)Подробнее

Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared HolzПодробнее

Pfizer is far behind weight loss drug race despite pill trial, says Mizuho's Jared HolzПодробнее

Weight loss drug market is just beginning to take off, says Mizuho's Jared HolzПодробнее

It's Not What You ThinkПодробнее

High profitability is the best way to pick tech stocks: Cornerstone Macro's Michael KantrowitzПодробнее

FLEXIBLE DIETING INSTITUTE Research Reviews - 42: The Science of Hunger (V): MacronutrientsПодробнее

Michael Levitt -Solving Large Macromolecular Complexes with Less Data and More ComputationПодробнее

[MIND 2018] Yaroslav Halchenko: Tools from the Center for Open NeuroscienceПодробнее

Toolkit Talk: Mastery LearningПодробнее

1-Alexander Slocum: Gizmos, Precision Engineering, Fat Rabbits, and Low-Hanging FruitПодробнее

The Smart Surface - monitoring cells for treatmentПодробнее